Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atux Iskay PP2A activator compounds
- Development stage
- Preclinical
- Lead developer
- Atux Iskay Group
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Atux Iskay Group is developing a pipeline of prototype small-molecule activators of Protein Phosphatase 2A (PP2A) designed to treat transcriptionally addicted and Ras-driven cancers. PP2A is a critical tumor suppressor phosphatase that is often functionally inactivated in various malignancies, leading to the constitutive activation of oncogenic signaling and transcriptional programs. These small molecules are intended to restore PP2A activity, thereby modulating key oncogenic drivers including the MYC and MYCN oncoproteins, the C-terminal domain (CTD) of RNA Polymerase II (RNAPII), and the Integrator-PP2A complex. By promoting the dephosphorylation of these targets, the compounds aim to disrupt the transcriptional machinery that fuels cancer cell survival and proliferation. The program is currently in the preclinical stage of development.
- Other names
- prototype PP2A activator compoundsPP2A activator compoundsPP-2A activator compoundsPP 2A activator compounds
02
Targets
PP2A (Protein phosphatase 2A)
Beyond the preview
Go deeper on Atux Iskay PP2A activator compounds.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atux Iskay PP2A activator compounds.